Based on existing data, it is estimated that 1 in 5 people will experience a mental health disorder at some point in their lives, with about 17% of the global population being affected in any given 12-month period [1]. Research on psychedelics was stagnant for decades due to its negative reputation and illegality; however, the field is now facing a renewal in research and clinical fields with regards to its therapeutic potential for psychiatric disorders [2]. Hallucinogenic drugs are placed in two categories: the “serotonergic classic hallucinogens,” which primarily agonize the 5-HT2A receptor, and the “dissociative hallucinogens,” which exert their pharmacological effects through the glutamatergic system [2]. Data on the neural effects of these hallucinogens have led to interest in their potential impact on the pathways involved in mental health disorders.
Classic psychedelic compounds interact with the 5-HT system, primarily as agonists of the 5-HT2A receptor; however, they exert other influences on the serotonin system as well. For example, LSD, psilocin, psilocybin and N,N-dimethyltryptamine (DMT) are known to interact with 5-HT1A, 5-HT2B, 5-HT2C, 5-HT6, and 5-HT7 receptors [2,3]. Clinical studies suggest the hallucinogenic properties induced by these drugs is a result of their interaction with the 5-HT receptors that impact translocation of β-arrestin, a family of intracellular proteins that are crucial in G-protein coupled receptor signaling [3,4]. In contrast to psilocin and DMT, LSD additionally shows affinity to dopaminergic D1-3 receptors, which suggests dopamine and the brain DA system plays a role in LSD’s effects [5].
Rodent studies indicate classic psychedelics, including LSD, psilocin, psilocybin, and DMT, as well as dissociative hallucinogens, i.e. ketamine, can induce anti-depressant effects, thus exerting influence on mental health outcomes [2,6]. Another preclinical study showed LSD could normalize anomalies in hippocampal monoamine receptor signaling that were present in a murine model of depression. Further, the authors suggested psychedelics may restore impaired avoidance learning, a behavioral effect of many depressive disorders, particularly major depressive disorder [2,7]. Mice with DMT in their system show some evidence of enhanced coping strategies in a forced swim test, the classic behavioral paradigm for depressive symptomology [8]. Recent neuroimaging studies suggest psychedelics such as LSD increase functional connectivity between the thalamus and sensory-somatomotor cortical regions, providing support for the theory that psychedelics exert anti-depressive influences through their strengthening of specific thalamocortical connections [9].
Ketamine is unique among hallucinogens, in that it is used at moderate to high doses for anesthesia. In low doses, some research reports that it exhibits fast-acting anti-depressant effects. In 2019, the FDA approved the first new anti-depressant medication in decades: esketamine, which is derived from ketamine compounds [10]. Most psychiatric medications are only effective while they are in the body; patients on medication therapies alone who stop briefly are at high risk of quickly relapsing. In contrast, ketamine’s effects may be more long-lasting, making it uniquely effective as an anti-depressant [11]. Ketamine is an antagonist of N-methyl-D-aspartate receptor (NMDAR), a glutamatergic receptor type expressed in the CNS [12]; research suggests that NMDAR antagonists improve symptoms by restoring excitatory connections in the brain, specifically by causing mTORC1 pathway activation [13]. In mice, ketamine’s anti-depressant effects were nullified when it was unable to metabolize to (2S,6S;2R,6R)-hydroxynorketamine (HNK) [14]. The value of repeated doses of ketamine over time as an anti-depressant is unclear [15].
Recent research has illuminated intricacies of hallucinogens for mental health; in addition to having anti-depressive effects, these drugs are being studied for the treatment of other mental disorders. For example, studies examining the use of psilocybin to treat alcohol-use disorder and obsessive-compulsive disorder seem promising [2]. It becomes paramount to look past the notoriety and stigma surrounding hallucinogens because they represent an important tool to better understanding brain pathology in mental health and psychiatric illness.
References
- Charlson, F., van Ommeren, M., Flaxman, A., Cornett, J., Whiteford, H., & Saxena, S. (2019). New WHO prevalence estimates of mental disorders in conflict settings: A systematic review and meta-analysis. The Lancet, 394(10194), 240–248. https://doi.org/10.1016/S0140-6736(19)30934-1
- Gregorio, D. D., Aguilar-Valles, A., Preller, K. H., Heifets, B. D., Hibicke, M., Mitchell, J., & Gobbi, G. (2021). Hallucinogens in mental health: Preclinical and clinical studies on LSD, psilocybin, MDMA, and ketamine. Journal of Neuroscience, 41(5), 891–900. https://doi.org/10.1523/JNEUROSCI.1659-20.2020
- Wacker, D., Wang, S., McCorvy, J. D., Betz, R. M., Venkatakrishnan, A. J., Levit, A., Lansu, K., Schools, Z. L., Che, T., Nichols, D. E., Shoichet, B. K., Dror, R. O., & Roth, B. L. (2017). Crystal structure of an lsd-bound human serotonin receptor. Cell, 168(3), 377-389.e12. https://doi.org/10.1016/j.cell.2016.12.033
- Luttrell, L. M., & Lefkowitz, R. J. (2002). The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals. Journal of Cell Science, 115(Pt 3), 455–465. https://doi.org/10.1242/jcs.115.3.455
- Rickli, A., Moning, O. D., Hoener, M. C., & Liechti, M. E. (2016). Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. European Neuropsychopharmacology, 26(8), 1327–1337. https://doi.org/10.1016/j.euroneuro.2016.05.001
- Hibicke, M., Landry, A. N., Kramer, H. M., Talman, Z. K., & Nichols, C. D. (2020). Psychedelics, but not ketamine, produce persistent antidepressant-like effects in a rodent experimental system for the study of depression. ACS Chemical Neuroscience, 11(6), 864–871. https://doi.org/10.1021/acschemneuro.9b00493
- Buchborn, T., Schröder, H., Höllt, V., & Grecksch, G. (2014). Repeated lysergic acid diethylamide in an animal model of depression: Normalization of learning behavior and hippocampal serotonin 5-HT 2 signalling. Journal of Psychopharmacology, 28(6), 545–552. https://doi.org/10.1177/0269881114531666
- Cameron, L. P., Benson, C. J., Dunlap, L. E., & Olson, D. E. (2018). Effects of n,n-dimethyltryptamine on rat behaviors relevant to anxiety and depression. ACS Chemical Neuroscience, 9(7), 1582–1590. https://doi.org/10.1021/acschemneuro.8b00134
- Preller, K. H., Burt, J. B., Ji, J. L., Schleifer, C. H., Adkinson, B. D., Stämpfli, P., Seifritz, E., Repovs, G., Krystal, J. H., Murray, J. D., Vollenweider, F. X., & Anticevic, A. (2018). Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor. ELife, 7, e35082. https://doi.org/10.7554/eLife.35082
- Commissioner, Office of the. (2020, March 24). FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor’s office or clinic. FDA. https://www.fda.gov/news-events/press-announcements/fda-approves-new-nasal-spray-medication-treatment-resistant-depression-available-only-certified
- Chen, J. How ketamine drug helps with depression. (2019, March 21). Yale Medicine. Updated March 9, 2022. https://www.yalemedicine.org/news/ketamine-depression
- Zorumski, C. F., Izumi, Y., & Mennerick, S. (2016). Ketamine: NMDA receptors and beyond. The Journal of Neuroscience, 36(44), 11158–11164. https://doi.org/10.1523/JNEUROSCI.1547-16.2016
- Workman, E. R., Niere, F., & Raab-Graham, K. F. (2018). Engaging homeostatic plasticity to treat depression. Molecular Psychiatry, 23(1), 26–35. https://doi.org/10.1038/mp.2017.225
- Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., Dossou, K. S. S., Fang, Y., Huang, X.-P., Mayo, C. L., Wainer, I. W., Albuquerque, E. X., Thompson, S. M., Thomas, C. J., Zarate Jr, C. A., & Gould, T. D. (2016). NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature, 533(7604), 481–486. https://doi.org/10.1038/nature17998
- Shiroma, P. R., Thuras, P., Wels, J., Albott, C. S., Erbes, C., Tye, S., & Lim, K. O. (2020). A randomized, double-blind, active placebo-controlled study of efficacy, safety, and durability of repeated vs. single subanesthetic ketamine for treatment-resistant depression. Translational Psychiatry, 10(1), 1–9. https://doi.org/10.1038/s41398-020-00897-0
Recent Comments